trump and glp 1 meds The “Fauxzempic” Crisis: Counterfeit Innovation Puts Lives—and Markets—at Risk Big News: GLP-1 medicine prices
Description
Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, et al
July 12, 2022
10.1038/s42255-023-00811-0
Compounded tirzepatide may be part of a provider-guided plan during this stage
The team will study the effects of GLP-1 drugs on five disproportionately burdened populations: racially minoritized groups, individuals of low socioeconomic status, rural and non-metro populations, people living with disabilities, and sexual and gender minorities
Liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks in adolescents with obesity, while placebo reduced BMI by 0.3% in the long term [115]
